Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment
| Autor: | Terzi, M., Helvacı, E.M., Şen, S., Boz, C., Çilingir, V., Akçalı, A., Beckmann, Y., Ünal, Aysun |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: |
safety
hypotension leukocyte count drug safety Efficacy clinical evaluation retrospective study heart infarction multiple sclerosis tachycardia bradycardia Article male demographics paced auditory serial addition test teriflunomide follow up human fingolimod nuclear magnetic resonance imaging contusion lymphocyte count dizziness dimethyl fumarate digit symbol substitution test adult blood pressure hypertransaminasemia 25 step walking test pruritus major clinical study body mass drug efficacy Expanded Disability Status Scale aged female lymphocytopenia drug withdrawal lipid fingerprinting nine hole peg test headache |
| Popis: | Introduction: Fingolimod is the first oral immunomodulatory treatment used as secondary care therapy in the treatment of multiple sclerosis for the last 10 years. The objective of our study is to reveal the experiences of the first generic fingolimod active ingredient treatment in different centers across Turkey. Method: The first generic fingolimod efficacy and safety data of patients followed-up in 29 different clinical multiple sclerosis units in Turkey were analyzed retrospectively. Data regarding efficacy and safety of the patients were transferred to the data system both before the treatment and on the 6th, 12th and 24th month following the treatment. The data were analyzed using the IBM SPSS 20.00. P value of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|